TEMPEST THERAPEUTICS INC (TPST) Stock Price, Quote, News and Overview
NASDAQ:TPST - Nasdaq - US87978U2078 - Common Stock - Currency: USD
TPST Quote, Performance and Key Statistics
5.95
-0.18 (-2.94%)
The current stock price of TPST is 5.95 USD. In the past month the price decreased by -13.14%. In the past year, price decreased by -86.21%.
TPST Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.12 | 328.74B | ||
| AMGN | AMGEN INC | 13.88 | 154.96B | ||
| GILD | GILEAD SCIENCES INC | 14.22 | 136.93B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.52B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.06 | 52.94B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.71B | ||
| ARGX | ARGENX SE - ADR | 97.66 | 35.00B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.28 | 26.55B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.03B | ||
| NTRA | NATERA INC | N/A | 21.54B | ||
| BIIB | BIOGEN INC | 8.2 | 19.02B | ||
| UTHR | UNITED THERAPEUTICS CORP | 12.72 | 14.38B |
Related stock screener links
About TPST
Company Profile
Tempest Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Brisbane California, California and currently employs 24 full-time employees. The company went IPO on 2012-10-04. Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Company Info
TEMPEST THERAPEUTICS INC
2000 Sierra Point Parkway, Suite 400
Brisbane California CALIFORNIA US
CEO: Louis Arcudi
Employees: 24
Phone: 14157988589
TEMPEST THERAPEUTICS INC / TPST FAQ
What is the stock price of TEMPEST THERAPEUTICS INC today?
The current stock price of TPST is 5.95 USD. The price decreased by -2.94% in the last trading session.
What is the ticker symbol for TEMPEST THERAPEUTICS INC stock?
The exchange symbol of TEMPEST THERAPEUTICS INC is TPST and it is listed on the Nasdaq exchange.
On which exchange is TPST stock listed?
TPST stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TEMPEST THERAPEUTICS INC stock?
10 analysts have analysed TPST and the average price target is 69.36 USD. This implies a price increase of 1065.71% is expected in the next year compared to the current price of 5.95. Check the TEMPEST THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TEMPEST THERAPEUTICS INC worth?
TEMPEST THERAPEUTICS INC (TPST) has a market capitalization of 21.90M USD. This makes TPST a Nano Cap stock.
How many employees does TEMPEST THERAPEUTICS INC have?
TEMPEST THERAPEUTICS INC (TPST) currently has 24 employees.
What are the support and resistance levels for TEMPEST THERAPEUTICS INC (TPST) stock?
TEMPEST THERAPEUTICS INC (TPST) has a resistance level at 6.31. Check the full technical report for a detailed analysis of TPST support and resistance levels.
Should I buy TEMPEST THERAPEUTICS INC (TPST) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TPST, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TPST, evaluating the profitability, health, valuation and growth aspects
- TEMPEST THERAPEUTICS INC (TPST) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TEMPEST THERAPEUTICS INC (TPST) Sales and EPS estimates to see what analysts future expectations are.
- TEMPEST THERAPEUTICS INC (TPST) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TEMPEST THERAPEUTICS INC (TPST) Insider and Institutional Ownership to learn about the owners and their transactions.
- TEMPEST THERAPEUTICS INC (TPST) Stock Chart to make your own analysis
- TEMPEST THERAPEUTICS INC (TPST) Latest news and press-releases to stay up to date.
Does TEMPEST THERAPEUTICS INC (TPST) stock pay dividends?
TPST does not pay a dividend.
When does TEMPEST THERAPEUTICS INC (TPST) report earnings?
TEMPEST THERAPEUTICS INC (TPST) will report earnings on 2025-08-06, after the market close.
What is the Price/Earnings (PE) ratio of TEMPEST THERAPEUTICS INC (TPST)?
TEMPEST THERAPEUTICS INC (TPST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-17.98).
TPST Technical Analysis
TPST Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TPST. The financial health of TPST is average, but there are quite some concerns on its profitability.
TPST Financial Highlights
Over the last trailing twelve months TPST reported a non-GAAP Earnings per Share(EPS) of -17.98. The EPS increased by 21.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -139.28% | ||
| ROE | -402.4% | ||
| Debt/Equity | 0 |
TPST Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to TPST. The Buy consensus is the average rating of analysts ratings from 10 analysts.